Citations 3
Sorafenib for Advanced and Refractory Desmoid Tumors
Gounder, Mrinal M. , Mahoney, Michelle R., Ravi, Vinod , Attia, Steven , Deshpande, Hari A. , Milhem, Mohammed , Conry, Robert M. , Movva, Sujana , Pishvaian, Michael J. , Riedel, Richard F. , Sabagh, Tarek, Tap, William D. , Horvat, Natally , Basch, Ethan , Schwartz, Lawrence H., Maki, Robert G. , Agaram, Narasimhan P. , Lefkowitz, Robert A. , Mazaheri, Yousef , Yamashita, Rikiya , Wright, John J., Dueck, Amylou C. , Van Tine, Brian A, Gupta, Abha A. , Milhem, Mohammed M, Schwartz, Gary K. , Dueck, A. C. , Maki, Robert G , Milhem, Mohammed M , Riedel, Richard F , Horvat, Natally , Tine, Brian A. Van , Basch, Ethan , Wright, John J.
New England Journal of Medicine | December 19, 2018 | Volume: 379 | Issue: 25 | Pages: 2417-2428
Phase III, randomized, double blind, placebo-controlled trial of sorafenib in desmoid tumors (Alliance A091105).
Gounder, Mrinal M. , Mahoney, Michelle R., Tine, Brian Andrew Van, Ravi, Vinod , Attia, Steven , Deshpande, Hari A. , Conry, Robert M. , Movva, Sujana , Pishvaian, Michael J. , Crawford, Jeffrey , Sabagh, Tarek, Tap, William D. , Lefkowitz, Robert A. , Agaram, Narasimhan P. , Wright, John Joseph, Gupta, Abha A. , Milhem, Mohammed , Maki, Robert G. , Dueck, Amylou C. , Schwartz, Gary K.
Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 11500-11500
N0234: Phase II study of erlotinib (OSI-774) plus gemcitabine as first-or second-line therapy for metastatic breast cancer (MBC)
Graham, David L. , Hobday, Timothy J. , Rousey, Steven R., Nair, Sreekumar, Soori, Gamini S. , Sabagh, Tarek, Perez, Edith A. , Hillman, David W.
Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 644-644